Merus to Publish Abstracts for Presentation at the 2024 ASCO Annual Meeting

DENVER, Colo., May 24, 2024 ( Merus N.V. (Nasdaq:MRUS) stated that the Company published abstracts for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, May 31-June 4, 2024, and website.

“We believe petosemtamab continues to demonstrate potential best in class safety and efficacy in head and neck cancer. We are encouraged with the well tolerated safety profile of the combination of petosemtamab and pembrolizumab, particularly with a low rate of Grade 3 or greater adverse events, and a low rate of infusion-related reactions observed,” commented Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “These data in the abstract provide encouraging efficacy albeit from an early cutoff date, with less mature data. And we look forward to our conference call, Tuesday May 28, to discuss the more mature clinical update from a later cutoff date where the response rate further improved.”

“We continue to be proud of our Multiclonics® technology platforms’ ability to develop bispecific antibodies for clinical investigation with the potential to impact patients’ lives,” Lundberg continued. “MCLA-129 continues to show strong monotherapy activity in EGFR mutant non-small cell lung cancer, and MCLA-145 is now the fourth molecule based on our technology to demonstrate clinical activity. We are looking forward to providing additional detail at 2024 ASCO.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to for disclaimer information.

24/7 Market News
[email protected]

Related news for (Nasdaq:MRUS)

    NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.